Authors: KALDEN J

Citation: J. Kalden, NEW TRENDS IN IMMUNOASSAY METHODOLOGY, CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 36(6), 1998, pp. 339-340

Authors: LIPSKY P STCLAIR W KAVANAUGH A MCCUNE W SMOLEN J BREEDVELD F FURST D KALDEN J WEISSMAN M BRAAKMAN T SCHAIBLE T MAINI R

Citation: P. Lipsky et al., LONG-TERM CONTROL OF SIGNS AND SYMPTOMS OF RHEUMATOID-ARTHRITIS WITH CHIMERIC MONOCLONAL ANTI-TNF-ALPHA ANTIBODY (INFLIXIMAB) IN PATIENTS WITH ACTIVE DISEASE ON METHOTREXATE, Arthritis and rheumatism, 41(9), 1998, pp. 1988-1988

Authors: ALSALAMEH S MANGER B KERN P KALDEN J

Citation: S. Alsalameh et al., NEW-ONSET OF RHEUMATOID-ARTHRITIS DURING INTERFERON BETA-1B TREATMENTIN A PATIENT WITH MULTIPLE-SCLEROSIS - COMMENT ON THE CASE-REPORT BY JABAILY AND THOMPSON, Arthritis and rheumatism, 41(4), 1998, pp. 754-754

Authors: KALDEN J MARION TN

Citation: J. Kalden et Tn. Marion, ENVIRONMENTAL AND OTHER STIMULI FOR DNA ANTIBODY-PRODUCTION, Lupus, 6(3), 1997, pp. 324-325

Authors: ANTONI C KAVANAUGH A RASCU A BRAAKMAN T MANGER B KALDEN J

Citation: C. Antoni et al., STANDARDIZATION OF JOINT EVALUATION PRIOR TO A MULTICENTER RHEUMATOID-ARTHRITIS (RA) TRIAL REDUCES VARIABILITY AMONG EXAMINERS, Arthritis and rheumatism, 40(9), 1997, pp. 386-386

Authors: ANTONI C MANGER B REICHSTETTER S SMOLEN J BREEDVELD F MAINI R BIJL H DEWOODY K KALDEN J WASSMUTH R

Citation: C. Antoni et al., THE HLA DR LOW AND DR4 HIGH-RESOLUTION BACKGROUND OF 55 PATIENTS WITHRHEUMATOID-ARTHRITIS TREATED WITH CA2 ANTIBODY AGAINST TUMOR-NECROSIS-FACTOR IN A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, Arthritis and rheumatism, 39(9), 1996, pp. 1298-1298